Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
Side-by-side research view
Compare names across metrics and research quality
Use up to 4 U.S.-listed names from this dashboard to compare valuation, growth, cash flow, balance-sheet strength, and the curated investment case in one place.
1 stocks in current compare
4 max names side by side
25 shared metrics lined up
Build a compare set
Enter comma-separated tickers from the dashboard universe. Duplicate tickers are ignored automatically.
Price
$339.03
1D change
+0.47%
Market cap
$130.04B
Sector
Healthcare
| Metric | SYK |
|---|---|
| Price | $339.03 |
| 1D Change | +0.47% |
| Market Cap | $130.04B |
| Enterprise Value | $142.01B |
| Trailing P/E | 35.1 |
| Forward P/E | 20.2 |
| PEG Ratio | 1.59x |
| Price / Sales | 5.0 |
| EV / Revenue | 5.5 |
| Revenue Growth | 9.4% |
| Earnings Growth | 44.1% |
| Gross Margin | 65.6% |
| Operating Margin | 27.0% |
| Net Margin | 14.4% |
| ROE | 16.5% |
| Free Cash Flow | $4.11B |
| FCF Margin | 15.9% |
| Debt / Equity | 0.64x |
| Current Ratio | 2.16x |
| Dividend Yield | 1.04% |
| Next Earnings | Oct 29, 2026 |
| Quarterly Revenue | $6.59B |
| Revenue QoQ | +9.5% |
| Quarterly Net Income | $1.28B |
| Net Income QoQ | +71.3% |
SYK thesis lens
Orthopedic robotics platform
Why it could benefit
- Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
- Recent expansion into handheld robotics broadens the Mako platform and gives the sleeve another real medical-robotics leader.
- It adds exposure to hospital robotics without relying on the exact same thesis as Intuitive.
Moat / edge
- Established Mako installed base and surgeon workflow integration.
- Strong orthopedic distribution and clinical relationships.
- A robotics platform that can expand across procedures over time.
What to watch
- Mako placements and utilization.
- Adoption of new handheld robotics offerings.
- How much robotics continues to differentiate Stryker in orthopedics.
Key risks
- Hospital budgets and elective procedure trends can affect demand.
- The robotics narrative is important, but it still sits inside a broader medtech company.